blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2522671

EP2522671 - Modulators of 5-HT receptors and methods of use thereof [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.11.2016
Database last updated on 24.08.2024
Most recent event   Tooltip01.05.2020Change - lapse in a contracting statepublished on 03.06.2020  [2020/23]
Applicant(s)For all designated states
AbbVie Inc.
1 North Waukegan Road
North Chicago, IL 60064 / US
For all designated states
AbbVie Deutschland GmbH & Co KG
Max-Planck-Ring 2a
65205 Wiesbaden / DE
[2013/42]
Former [2013/24]For all designated states
AbbVie Inc.
1 North Waukegan Road
North Chicago, IL 60064 / US
For all designated states
Abbott GmbH & Co. KG
Max-Planck-Ring 2
65205 Wiesbaden / DE
Former [2012/46]For all designated states
Abbott Laboratories
100 Abbott Park Road
Abbott Park, Illinois 60064-6008 / US
For all designated states
Abbott GmbH & Co. KG
Max-Planck-Ring 2
65205 Wiesbaden / DE
Inventor(s)01 / Wang, Ying
18833 Chatham Way
Lake Villa, IL Illinois 60046 / US
02 / Brewer, Jason, T.
3901 Harmony Court
Zion, IL Illinois 60099 / US
03 / Akritopoulou-Zanze, Irini
1817 South Waxwing Lane
Libertyville, IL Illinois 60048 / US
04 / Djuric, Stevan, W.
621 Paddock Lane
Libertyville, IL Illinois 60048 / US
05 / Pohlki, Frauke
Neustadter Strasse 20
67112 Mutterstadt / DE
06 / Braje, Wilfried
Emil-Heckel-Str. 4
68163 Mannheim / DE
07 / Relo, Ana-Lucia
Romerweg 12
67161 Gonnheim / DE
 [2012/46]
Representative(s)Modiano, Micaela Nadia, et al
Modiano & Partners (DE)
Thierschstrasse 11
80538 München / DE
[2012/46]
Application number, filing date12175535.922.04.2010
[2012/46]
Priority number, dateUS20090171912P23.04.2009         Original published format: US 171912 P
[2012/46]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2522671
Date:14.11.2012
Language:EN
[2012/46]
Type: A3 Search report 
No.:EP2522671
Date:24.04.2013
Language:EN
[2013/17]
Type: B1 Patent specification 
No.:EP2522671
Date:20.01.2016
Language:EN
[2016/03]
Search report(s)(Supplementary) European search report - dispatched on:EP27.03.2013
ClassificationIPC:C07D498/04, C07D471/04, C07D471/14, C07D487/04, C07D491/04, // A61K31/4985, A61K31/551, A61K31/553, A61P25/00
[2012/46]
CPC:
C07D498/04 (EP,CN); C07D487/04 (EP,CN); A61P1/00 (EP);
A61P1/04 (EP); A61P1/14 (EP); A61P13/02 (EP);
A61P13/10 (EP); A61P15/00 (EP); A61P15/10 (EP);
A61P17/06 (EP); A61P25/00 (EP); A61P25/04 (EP);
A61P25/06 (EP); A61P25/08 (EP); A61P25/10 (EP);
A61P25/14 (EP); A61P25/16 (EP); A61P25/18 (EP);
A61P25/20 (EP); A61P25/22 (EP); A61P25/24 (EP);
A61P25/28 (EP); A61P25/30 (EP); A61P25/34 (EP);
A61P25/36 (EP); A61P27/02 (EP); A61P27/06 (EP);
A61P3/04 (EP); A61P3/10 (EP); A61P43/00 (EP);
A61P7/12 (EP); A61P9/10 (EP); A61P9/12 (EP);
C07D471/04 (EP,CN); C07D471/14 (EP); C07D487/14 (CN);
C07D491/04 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2016/03]
Former [2012/46]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
TitleGerman:5-HT-Rezeptor-Modulatoren und Verfahren zu ihrer Verwendung[2012/46]
English:Modulators of 5-HT receptors and methods of use thereof[2012/46]
French:Modulateurs de récepteurs 5-HT et leurs procédés d'utilisation[2012/46]
Examination procedure11.11.2013Amendment by applicant (claims and/or description)
11.11.2013Examination requested  [2013/51]
05.12.2013Despatch of a communication from the examining division (Time limit: M04)
15.04.2014Reply to a communication from the examining division
29.09.2014Despatch of a communication from the examining division (Time limit: M06)
08.04.2015Reply to a communication from the examining division
08.07.2015Communication of intention to grant the patent
11.11.2015Fee for grant paid
11.11.2015Fee for publishing/printing paid
11.11.2015Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP10716195.2  / EP2421870
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20100716195) is  11.04.2014
Opposition(s)21.10.2016No opposition filed within time limit [2016/52]
Request for further processing for:The application is deemed to be withdrawn due to non-payment of designation fees
PT, EE, TR, SM, SK, SI, SE, RO, PL, NO, NL, MT, MK, MC, LV, LU, LT, IT, IS, IE, HU, HR, GR, GB, FR, FI, ES, DK, DE, CZ, CY, CH, BG, BE, AT
11.11.2013Request for further processing filed
11.11.2013Full payment received (date of receipt of payment)
Request granted
22.11.2013Decision despatched
The application is deemed to be withdrawn due to non-payment of the examination fee
11.11.2013Request for further processing filed
11.11.2013Full payment received (date of receipt of payment)
Request granted
22.11.2013Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
11.11.2013Request for further processing filed
11.11.2013Full payment received (date of receipt of payment)
Request granted
22.11.2013Decision despatched
Fees paidRenewal fee
09.07.2012Renewal fee patent year 03
26.03.2013Renewal fee patent year 04
26.03.2014Renewal fee patent year 05
08.04.2015Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.04.2010
AT20.01.2016
BE20.01.2016
CY20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
MC20.01.2016
MK20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SI20.01.2016
SK20.01.2016
SM20.01.2016
TR20.01.2016
BG20.04.2016
NO20.04.2016
GR21.04.2016
IE22.04.2016
LU22.04.2016
CH30.04.2016
LI30.04.2016
MT30.04.2016
IS20.05.2016
PT20.05.2016
[2020/23]
Former [2018/31]HU22.04.2010
AT20.01.2016
BE20.01.2016
CY20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
MC20.01.2016
MK20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SI20.01.2016
SK20.01.2016
SM20.01.2016
TR20.01.2016
BG20.04.2016
NO20.04.2016
GR21.04.2016
IE22.04.2016
LU22.04.2016
CH30.04.2016
LI30.04.2016
MT30.04.2016
IS20.05.2016
PT20.05.2016
Former [2018/29]HU22.04.2010
AT20.01.2016
BE20.01.2016
CY20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
MC20.01.2016
MK20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SI20.01.2016
SK20.01.2016
SM20.01.2016
TR20.01.2016
BG20.04.2016
NO20.04.2016
GR21.04.2016
IE22.04.2016
LU22.04.2016
CH30.04.2016
LI30.04.2016
IS20.05.2016
PT20.05.2016
Former [2018/28]HU22.04.2010
AT20.01.2016
BE20.01.2016
CY20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
MC20.01.2016
MK20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SI20.01.2016
SK20.01.2016
SM20.01.2016
BG20.04.2016
NO20.04.2016
GR21.04.2016
IE22.04.2016
LU22.04.2016
CH30.04.2016
LI30.04.2016
IS20.05.2016
PT20.05.2016
Former [2017/38]AT20.01.2016
BE20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SI20.01.2016
SK20.01.2016
SM20.01.2016
BG20.04.2016
NO20.04.2016
GR21.04.2016
IE22.04.2016
LU22.04.2016
CH30.04.2016
LI30.04.2016
IS20.05.2016
PT20.05.2016
Former [2017/16]AT20.01.2016
BE20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SI20.01.2016
SK20.01.2016
SM20.01.2016
BG20.04.2016
NO20.04.2016
GR21.04.2016
LU22.04.2016
CH30.04.2016
LI30.04.2016
IS20.05.2016
PT20.05.2016
Former [2017/07]AT20.01.2016
BE20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SK20.01.2016
SM20.01.2016
NO20.04.2016
GR21.04.2016
LU22.04.2016
CH30.04.2016
LI30.04.2016
IS20.05.2016
PT20.05.2016
Former [2017/04]AT20.01.2016
BE20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SK20.01.2016
SM20.01.2016
NO20.04.2016
GR21.04.2016
LU22.04.2016
IS20.05.2016
PT20.05.2016
Former [2017/03]AT20.01.2016
BE20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SK20.01.2016
SM20.01.2016
NO20.04.2016
GR21.04.2016
IS20.05.2016
PT20.05.2016
Former [2016/50]AT20.01.2016
CZ20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
NL20.01.2016
PL20.01.2016
RO20.01.2016
SE20.01.2016
SK20.01.2016
SM20.01.2016
NO20.04.2016
GR21.04.2016
BE30.04.2016
IS20.05.2016
PT20.05.2016
Former [2016/49]AT20.01.2016
DK20.01.2016
EE20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
NL20.01.2016
PL20.01.2016
SE20.01.2016
NO20.04.2016
GR21.04.2016
BE30.04.2016
IS20.05.2016
PT20.05.2016
Former [2016/46]AT20.01.2016
DK20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
NL20.01.2016
PL20.01.2016
SE20.01.2016
NO20.04.2016
GR21.04.2016
BE30.04.2016
IS20.05.2016
PT20.05.2016
Former [2016/39]AT20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
LV20.01.2016
NL20.01.2016
PL20.01.2016
SE20.01.2016
NO20.04.2016
GR21.04.2016
BE30.04.2016
IS20.05.2016
PT20.05.2016
Former [2016/38]AT20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
NL20.01.2016
PL20.01.2016
NO20.04.2016
GR21.04.2016
BE30.04.2016
IS20.05.2016
PT20.05.2016
Former [2016/36]AT20.01.2016
FI20.01.2016
HR20.01.2016
LT20.01.2016
NL20.01.2016
PL20.01.2016
NO20.04.2016
GR21.04.2016
BE30.04.2016
Former [2016/35]FI20.01.2016
HR20.01.2016
NL20.01.2016
NO20.04.2016
GR21.04.2016
Former [2016/30]NL20.01.2016
Documents cited:Search[XP]WO2009098236  (NOVARTIS AG [CH], et al) [XP] 1,12 * see example 12 on p. 78 *;
 [X]US2008188460  (CASARA PATRICK [FR], et al) [X] 1,10,12 * see preparation 17, steps I, J, K, L, M and N *;
 [X]EP0463691  (MERCK SHARP & DOHME [GB]) [X] 1,10,12 * see examples 2 and 3 *;
 [X]EP0206225  (MERCK PATENT GMBH [DE]) [X] 1,10,12 * see example 5, indole derivative and 5-hydroxyindole derivative *;
 [A]WO2008007661  (TAKEDA PHARMACEUTICAL [JP], et al) [A] 1-32,34 * see the structure of the pyrazinobenzoxazines and pyrazinobenzodiazepines according to claim 1 and activity as 5-HT2-receptor agonists *;
 [A]WO8807997  (UNIV MONASH [AU], et al) [A] 1-32,34 * see structure of the compounds of claim 1 and activity as 5-HT2-receptor anatgonists *;
 [XI]WO2005047252  (WYETH CORP [US], et al) [X] 33 * see claims 10 to 13 directed to methods of treatment of disorders related to the 5-HT6 receptor * [I] 33;
 [XI]WO2004074243  (WYETH CORP [US], et al) [X] 33 * see claims 10 to 14 directed to methods of treatment of disorders related to the 5-HT6 receptor * [I] 33;
 [XI]WO2007032833  (WYETH CORP [US], et al) [X] 33 * see claims 10 to 14 directed to methods of treatment of disorders related to the 5-HT6 receptor * [I] 33
 [X]  - RUSSELL, MICHAEL G. N. ET AL, "Benz[f]isoquinoline analogs as high-affinity .sigma. ligands", JOURNAL OF MEDICINAL CHEMISTRY , 35(11), 2025-33 CODEN: JMCMAR; ISSN: 0022-2623, (1992), XP009139166 [X] 1,10,12 * see compounds 44 and 45 in table IV on p. 2029 *

DOI:   http://dx.doi.org/10.1021/jm00089a012
 [X]  - BHANDARI, K. ET AL, "Agents acting on the central nervous system. Part XXXIV. 1,2,3,4,4a,5,6,7-Octahydropyrazino[1,2-a]-1-benzazepines", INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY , 25B(12), 1231-3 CODEN: IJSBDB; ISSN: 0376-4699, (1986), XP009139173 [X] 1,10,12 * see compounds IIc, IId, IIf and IIg in chart I on p. 1232 *
 [X]  - MUELLER, WERNER ET AL, "Seven-membered heterocyclics. Part 29. Synthesis of 1,2-annelated 1,4-benzodiazepines and 4,1-benzoxazepines", HELVETICA CHIMICA ACTA , 65(7), 2118-32 CODEN: HCACAV; ISSN: 0018-019X, (1982), XP009139171 [X] 1,12,20 * see compound 65 in scheme 5 and reduction of compound 7 with LiAlH4 to give compound 10 on p. 2120, l. 11 to 12. *

DOI:   http://dx.doi.org/10.1002/hlca.19820650719
 [X]  - SMITH, R. G. ET AL, "Synthesis and anxiolytic activity of a series of pyrazino[1,2-a][1,4]benzodiazepine derivatives", JOURNAL OF MEDICINAL CHEMISTRY , 23(8), 952-5 CODEN: JMCMAR; ISSN: 0022-2623, (1980), XP009139174 [X] 1,12,20 * see compounds 5a and 5b in scheme I on p. 953 *

DOI:   http://dx.doi.org/10.1021/jm00182a026
by applicantUS2007225277
 US2008146583
 US2007225274
    - "Dopamine in schizophrenia: a review and re-conceptualization", AM J PSYCHIATRY, (1991), vol. 148, pages 1474 - 86
    - WEINBERGER DR; BERMAN KF, "Prcfrontal function in schizophrenia: confounds and controversies", PHILOS TRANS R SOC LOND B BIOL SCI, (1996), vol. 351, pages 1495 - 503
    - REMINGTON G; KAPUR S, "Atypical antipsychotics: are some more atypical than others?", PSYCHOPHARMACOL, (2000), vol. 148, doi:doi:10.1007/s002130050017, pages 3 - 15, XP002483914

DOI:   http://dx.doi.org/10.1007/s002130050017
    - KAUFMAN MJ; HIRATA F, "Cyclic GMP inhibits phosphoiuositide turnover in choroid plexus: evidence for interactions between second messengers concurrently triggered by 5-HT2C receptors", NETRROSCI LETT, (1996), vol. 206, pages 153 - 156
    - POMPEIANO M; PALACIOS JM; MENGOD G, "Distribution of the scrotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HTzc receptors", BRAIN RES MOL BRAIN REV, (1994), vol. 23, pages 163 - 178
    - LOPEZ-GIMANEZ JF; MENGOD G; PALACIOS JM; VILARO MT, "Regional distribution and cellular localization of 5-HT2C receptor mRNA in monkey brain: comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA", SYNAPSE, (2001), vol. 42, pages 12 - 26
    - "IUPAC 1974 Recommendations for Section E", PURE APPL. CHEM., (1976), vol. 45, pages 13 - 30
    - BRYANT, H. U. ET AL., LIFE SCIENCES, (1996), vol. 59, no. 15, pages 1259 - 1268
    - MUNSON; RODBARD, ANAL. BIOCHEM., (1980), vol. 107, pages 220 - 239
    - FELDMAN, ANAL. BIOCHEM., (1972), vol. 48, pages 317 - 338
    - CHENG; PRUSOFF, BIOCHEM. PHARMACOL., (1973), vol. 22, pages 2099 - 2108
    - TECOTT LH; SUN LM; AKANA SF; STRACK AM; LOWENSTEIN DH; DALLMAN MF; JULIUS D, "Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors", NATURE, (1995), vol. 374, doi:doi:10.1038/374542a0, pages 542 - 546, XP001193395

DOI:   http://dx.doi.org/10.1038/374542a0
    - CHOU-GREEN JM; HOLSCHER TD; DALLMAN MF; AKANA SF, "Compulsive behavior in the 5-HT2c receptor knockout mouse", PHYS. BEHAV., (2003), vol. 78, pages 641 - 649
    - CHOU-GREEN JM; HOLSCHER TD; DALLMAN MF; AKANA SF, "Repeated stress in young and old 5-HT2c receptor knockout mouse", PHYS. BEHAV., (2003), vol. 79, pages 217 - 226
    - FRANK MG; STRYKER MP; TECOTT LH, "Sleep and sleep homeostasis in mice lacking the 5-HT2c receptor", NEUROPSYCHOPHARMACOLOGY, (2002), vol. 27, pages 869 - 873
    - ROCHA BA; GOULDING EH; O'DELL LE; MEAD AN; COUFAL NG; PARSONS LH; TECOTT LH, "Enhanced locomotor, reinforcing and neurochemical effects of cocaine in serotonin 5-hydroxytzyptamine 2C receptor mutant mice", J. NEUROSCI., (2002), vol. 22, pages 10039 - 10045
    - WERRY, TD; LOIACONO R; SEXTON PA; CHRISTOPOULOS A, "RNA editing ofthe seratonin 5-HT2C receptor and its effects on cell signaling, pharmacology and brain function", PHARMAC. THERAP., (2008), vol. 119, pages 7 - 23
    - SCHMAUSS C, "Serotonin 2C receptors: suicide, serotonin, and runaway RNA editing", NEUROSCIENTIST, (2003), vol. 9, doi:doi:10.1177/1073858403253669, pages 237 - 242, XP009033018

DOI:   http://dx.doi.org/10.1177/1073858403253669
    - IWAMOTO K; KATO T, "RNA editing of serotonin 2C receptor in human postmortem brains of major mental disorders", NEUROSCI. LETT., (2003), vol. 346, doi:doi:10.1016/S0304-3940(03)00608-6, pages 169 - 172, XP001182238

DOI:   http://dx.doi.org/10.1016/S0304-3940(03)00608-6
    - IWAMOTOA K; NAKATANIB N; BUNDOA M; YOSHIKAWAB T; KATOA T, "Altered RNA editing of serotonin 2C receptor in a rat model of depression", NEUROSCI. RES., (2005), vol. 53, pages 69 - 76
    - DU Y; STASKO M; COSTA AC; DAVISSONE MT; GARDINER KJ, "Editing of the serotonin 2C receptor pre-mRNA Effects of the Morris Water Maze", GENE, (2007), vol. 391, doi:doi:10.1016/j.gene.2006.12.023, pages 186 - 197, XP005917928

DOI:   http://dx.doi.org/10.1016/j.gene.2006.12.023
    - NISWENDER CM; HERRICK-DAVIS K; DILLEY GE; MELTZER HY; OVERHOLSER JC; STOCKMEIER CA; EMESON RB; SANDERS-BUSH E, "RNA Editing of the Human Serotonin 5-HT2c Receptor: Alterations in Suicide and Implications for Serotonergic", PHARMACOTHERAPY. NEUROPSYCHOPHARM, (2001), vol. 24, doi:doi:10.1016/S0893-133X(00)00223-2, pages 478 - 491, XP002288022

DOI:   http://dx.doi.org/10.1016/S0893-133X(00)00223-2
    - SMITH BM ET AL., "Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity", J MED CHEM, (2008), vol. 51, doi:doi:10.1021/jm0709034, pages 305 - 313, XP009138515

DOI:   http://dx.doi.org/10.1021/jm0709034
    - THOMSEN WJ; GROTTICK AJ; MENZAGHI F; REYES-SALDANA H; ESPITIA S; YUSKIN D; WHELAN K; MARTIN M; MORGAN M; CHEN W, "Lorcaserin, A Novel Selective Human 5-HT2c Agonist: In Vitro and In Vivo Pharmacological Characterization", J PHARMACOL EXP THER., (2008), vol. 325, doi:doi:10.1124/jpet.107.133348, pages 577 - 587, XP009138374

DOI:   http://dx.doi.org/10.1124/jpet.107.133348
    - ROSENZWEIG-LIPSON S; ZHANG J; MAZANDARANI H; HARRISON BL; SABB A; SABALSKI J; STACK G; WELMAKER G; BARRETT JE; DUNLOP J, "Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503", BRAIN RES., (2006), vol. 1073-107, doi:doi:10.1016/j.brainres.2005.12.052, pages 240 - 251, XP025064592

DOI:   http://dx.doi.org/10.1016/j.brainres.2005.12.052
    - DUNLOP J; SABB AL; MAZANDARANI H; ZHANG J; KALGAONKER S; SHUKHINA E; SUKOFF S; VOGEL RL; STACK G; SCHECHTER L, J PHARMACAL EXP THER., vol. 313, pages 862 - 869
    - ROSENZWEIG-LIPSON S; SABB A; STACK G; MITCHELL P; LUCKI I; MALBERG JE; GRAUER S; BRENNAN J; CLYAN JF; SUKOFF RIZZO SJ, "Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents", PSYCHOPHARMACOLOGY (BERLIN, (2007), vol. 192, pages 159 - 170, XP002450646
    - ROSENZWEIG-LIPSON S; DUNLOP J; MARQUIS KL, "5-HT2c receptor agonists as an innovative approach for psychiatric disorders", DRUG NEWS PERSPECT, (2007), vol. 20, pages 565 - 571
    - CRYAN, JF; LUCKI I, "Antidepressant-like behavioral effects mediated by 5-Hydroxytlyptamine 2C receptors", J. PHARRN. EXP. THER., (2000), vol. 295, pages 1120 - 1126, XP002450645
    - DI MATTCO, V.; DI GIOVANNI, G.; DI MASCIO, M.; ESPOSITO, E., "SB 242084, a selective serotonin 2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system", NEUROPHARMACOLOGY, (1999), vol. 38, pages 1195 - 1205
    - DI GIOVANNI, G.; DI MATTEO, V.; DI MASCIO, M.; ESPOSITO, E., "Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin2C/2B receptor agonists: a combined in vivo electrophysiological and microdialysis study", SYNAPSE, (2000), vol. 35, pages 53 - 61
    - MARQUIS KL; SABB AL; LOGUE SF; BRENNAN JA; PIESLA MJ; COMERY TA; GRAUER SM; ASHBY CR, JR.; NGUYEN HQ; DAWSON LA, "WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-actahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity", J PHARMACAL EXP THER, (2007), vol. 320, pages 486 - 496
    - MARQUIS KL; SABB AL; LOGUE SF; BRENNAN JA; PIESLA MJ; COMERY TA; GRAUER SM; ASHBY CR, JR.; NGUYEN HQ; DAWSON LA, "WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxyttyptamine 2C receptor-selective agonist with preclinical antipsychotics-like activity", J PHARMACOL EXP THER, (2007), vol. 320, pages 486 - 496
    - SIUCIAK JA; CHAPIN DS; MCCARTHY SA; GUANOWSKY V; BROWN J; CHIANG P; MARALA R; PATTERSON T; SEYMOUR PA; SWICK A, "CP-809,101, a selective 5-HT2c agonist, shows activity in animal models of antipsychotic activity", NEUROPHARMACOLOGY, (2007), vol. 52, doi:doi:10.1016/j.neuropharm.2006.07.024, pages 279 - 290, XP005856696

DOI:   http://dx.doi.org/10.1016/j.neuropharm.2006.07.024
    - ROSENZWEIG-LIPSON S; DUNLOP J; MARQUIS KL, "5-HT2c receptor agonists as an innovative approach for psychiatric disorders", DR-UG NEWS PERSPECT, (2007), vol. 20, pages 565 - 571
    - DUNLOP J; MARQUIS KL; LIM HK; LCUNG L; KAO J; CHEESMAN C; ROSENZWEIG-LIPSON S, "Pharmacological profile of the 5-HT2c receptor agonist WAY-163909; therapeutic potential in multiple indications", CNS DUG REV., (2006), vol. 12, pages 167 - 177, XP009089393
    - ISAAC M, "Serotonergic 5-HT2C receptors as a potential therapeutic target for the antiepileptic drugs", CURR TOPICS MED. CHEM., (2005), vol. 5, pages 59 - 67
    - THORSLUND K; NORDLIND K, "Serotoncrgic drugs-a possible role in the treatment of psoriasis?", DRUG NEWS PERSPECT, (2007), vol. 20, pages 521 - 525
    - ESPOSITO E; DI MATTEO V; PIERUCCI M; BENIGNO A; DI GIAVANNI, G, "Role of central S-HT2C receptor in the control of basal ganglia functions", THE BASAL GANGLIA PATHOPHYSIOLOGY: RECENT ADVANCES, (2007), pages 97 - 127
    - BARR AM; LAHMANN-MASTEN V; PAULUS M; GAINETDINOV RP; CARON MG; GEYER MA, "The selective serotonin-2A receptor antagonist M 100907 reverses behavioral deficits in dopamine transporter knockout mice", NEUROPSYCHOPHARMACOLOGY, (2004), vol. 29, doi:doi:10.1038/sj.npp.1300343, pages 221 - 228, XP003000531

DOI:   http://dx.doi.org/10.1038/sj.npp.1300343
    - DEKEYNE A; MANNOURY LA C'OUR C; GOBEIL A; BROCCO M; LEJUENE F; SERRES F; SHARP T; DASZUTA A; SOUMIOR A; PAPP M, "S32006, a novel 5-HT2C receptor antagonists displaying broad-based antidepressant and anxiolytic properties in rodent models", PSYCHORMACOLOGY, vol. 199, pages 549 - 568, XP019621119
    - NUNES-DE-SOUZA V; NUNES-DE-SOUZA RL; RODGERS RJ; CANTO-DE-SOUZA A, "5-HT2 receptor activation in the midbrain periaqueductal grey (PAG) reduces anxiety-like behavior in mice", BEHAV. BRAIN RES., (2008), vol. 187, doi:doi:10.1016/j.bbr.2007.08.030, pages 72 - 79, XP022382026

DOI:   http://dx.doi.org/10.1016/j.bbr.2007.08.030
    - LEONE M; RIGAMONTI A; D'AMICO D; GRAZZI L; USAI S; BUSSONE G, "The serotonergic system in migraine", JOURNAL OF HEADACHE AND PAIN, (2001), vol. 2, no. 1, pages S43 - S46, XP019361914
    - ARJONA AA; POOLER AM; LEE RK; WURTMAN RJ, "Effect of a 5-HT2C serotonin agonist, dexnorfenfluramine, on amyloid prccursor protein metabolism in guinea pigs", BRAIN RES., (2002), vol. 951, doi:doi:10.1016/S0006-8993(02)03153-0, pages 135 - 140, XP001149841

DOI:   http://dx.doi.org/10.1016/S0006-8993(02)03153-0
    - NAKAE A; NAKAI K; TANAKA T; HAGIHIRA S; SHIBATA M; UEDA K; MASIMO T, "The role of RNA editing of the serotonin 2C receptor in a rat model of oro-facial neuropathic pain", THE EUROPEAN JOURNAL OF NEUROSCIENCE, (2008), vol. 27, pages 2373 - 2379
    - NAKAE A; NAKAI K; TANAKA T; TAKASHINA M; HAGIHIRA S; SHIBATA M; UEDA K; MASHIMO T, "Serotonin 2C receptor mRNA editing in neuropathic pain model", NEUROSCI. RES., (2008), vol. 60, doi:doi:10.1016/j.neures.2007.10.004, pages 228 - 231, XP022439568

DOI:   http://dx.doi.org/10.1016/j.neures.2007.10.004
    - KAO T; SHUMSKY JS; JACOB-VADAKOT S; TIMOTHY HB; MURRAY M; MOXON, KA, "Role of the 5-HT2c receptor in improving weight-supported stepping in adult rats spinalized as neonates", BRAIN RES., (2006), vol. 1112, doi:doi:10.1016/j.brainres.2006.07.020, pages 159 - 168, XP025101348

DOI:   http://dx.doi.org/10.1016/j.brainres.2006.07.020
    - MOTOFEI IG, "A dual physiological character for sexual function: the role of serotonergic receptors", BJU INTERNATIONAL, (2008), vol. 101, doi:doi:10.1111/j.1464-410X.2007.07255.x, pages 531 - 534, XP008150187

DOI:   http://dx.doi.org/10.1111/j.1464-410X.2007.07255.x
    - SHIMADA I; MAENO K; KONDOH Y; KAKU H; SUGASAWA K; KIMURA Y; HATANAKA K; NAITOU Y; WANIBUCHI F; SAKAMOTO S, "Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists", BIOORG. MED. CHEM., (2008), vol. 16, doi:doi:10.1016/j.bmc.2007.12.009, pages 3309 - 3320, XP022558565

DOI:   http://dx.doi.org/10.1016/j.bmc.2007.12.009
    - FLETCHER PJ; LE AD, HIGGINS GA, "Serotonin receptors as potential targets for modulation of nicotine use and dependence", PROGRESS BRAIN RES., (2008), vol. 172, doi:doi:10.1016/S0079-6123(08)00918-7, pages 361 - 83, XP009183073

DOI:   http://dx.doi.org/10.1016/S0079-6123(08)00918-7
    - BUBAR MJ; CUNNINGHAM KA, "Prospects for serotonin 5-HT2R phaimacotherapy in psychostimulant abuse", PROGRESS BRAIN RES., (2008), vol. 172, doi:doi:10.1016/S0079-6123(08)00916-3, pages 319 - 46, XP009183072

DOI:   http://dx.doi.org/10.1016/S0079-6123(08)00916-3
    - SHARIF NA; MCLAUGHLIN MA; KELLY CR, "AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist", J OCUL PHARMACOL THER., (2006), vol. 23, doi:doi:10.1089/jop.2006.0093, pages 1 - 13, XP008109787

DOI:   http://dx.doi.org/10.1089/jop.2006.0093
    - OBATA, HIDEAKI; ITO, NAOMI; SASAKI, MASAYUKI; SAITO, SHIGERU; GOTO, FUMIO, "Possible involvement of spinal noradrenergic mechanisms in the antiallodynic effect of intrathecally administered 5 - HT2C receptor agonists in the rats with peripheral nerve injury", EUROPEAN JOURNAL OF PHARMACOLOGY, (2007), vol. 567, no. 1-2, doi:doi:10.1016/j.ejphar.2007.03.029, pages 89 - 94, XP022095316

DOI:   http://dx.doi.org/10.1016/j.ejphar.2007.03.029
    - NAKAE, AYA; NAKAI, KUNIHIRO; TANAKA, TATSUYA; TAKASHINA, MASAKI; HAGIHIRA, SATOSHI; SHIBATA, MASAHIKO; UEDA, KOICHI; MASHIMO, TAKA, "Department of Anesthesiology & Intensive Care Medicine", GRADUATE SCHOOL OF MEDICINE, OSAKA UNIVERSITY
    - "Antiallodynic effects of intrathecally administered 5 - HT2C receptor agonists in rats with nerve injury", NEUROSCIENCE RESEARCH, (2008), vol. 60, no. 2, pages 228 - 231
    - OBATA, HIDEAKI; SAITO, SHIGERU; SAKURAZAWA, SHINOBU; SASAKI, MASAYUKI; USUI, TADASHI; GOTO, FUMIO, "Department of Anesthesiology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan", PAIN, (2004), vol. 108, no. 1-2, pages 163 - 169
    - BRUS, RYSZARD; KASPERSKA, ALICJA; OSWIECIMSKA, JOANNA; SZKILNIK, RYSZARD, "Influence of 5 ,7-dihydroxytryptamine ( 5 ,7-DHT) on the antinociceptive effect of serotonin ( 5 -HT) 5 - HT2C receptor agonist in male and female rats", POL. A1EDICAL SCIENCE MONITOR, (1997), vol. 3, no. 5, pages 654 - 656
    - BRENNAN, PAUL E.; WHITLOCK, GAVIN A.; HO, DANNY K. H.; CONLON, KELLY; MCMURRAY, GORDON, "Discovery of a novel azcpine series of potent and selective 5 - HT2C agonists as potential treatments for urinary incontinence", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2009), vol. 19, no. 17, pages 4999 - 5003, XP026458544
    - MBAKI, Y.; RAMAGE, A. G., "Investigation of the role of 5 -HT2 receptor subtypes in the control of the bladder and the urethra in the anesthetized female rat", BRITISH JOURNAL OF PHARMACOLOGY, (2008), vol. 155, no. 3, pages 343 - 356
    - A1ethods in Cell Biology, ACADEMIC PRESS, (1976), vol. XIV, page 33
    - J. PHARMACEUTICAL SCIENCES, (1977), vol. 66, page 1
    - BANZATTI, C. ET AL., J. HETEROCYCLIC CHEMISTRY, (1983), pages 139 - 144
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.